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to elucidate associations with therapeutic responses or prognosis, and func-
tional analysis of these candidate genes in CML cell lines is required to confirm
these findings.
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Background:Atypical chronic myeloid leukemia (aCML) is an haematological
neoplasm characterized by a median overall survival of 12.4 months. The stan-
dard treatments for aCML patients are chemotherapeutic drugs. However, these
treatments result inefficient in inducing remission from the pathology. Recently
we demonstrated that the haploinsufficiency of Morgana, an Hsp90 co-chap-
erone, in vivo is sufficient to induce a lethal and transplantable CML-like myeloid
neoplasm characterized by non recurrent cytogenetic abnormalities in the bone
marrow. Morgana is able to bind to and inhibit Rho-kinases, which are emerging
as key oncogenic players in haematological disorders
Aims: Identify fundamental altered pathways in aCML to uncover the biological
basis of the disease and find new therapeutical targets.
Methods: The bone marrow of morgana heterozygous mice and chronic
myeloid leukemia patients has been analyzed extensively by flow cytometry
and immunoistochemestry. Murine and human CML bone marrow cells and in
vitro cellular models (K562 and THP-1 cells) have been tested for sensitivity to
the ROCK inhibitor Fasudil. 
Results: We demonstrated that diseased morgana heterozygous mice show
ROCK hyperactivation in the bone marrow and that inhibition of these kinases
results in apoptosis of morganalow bone marrow leukemic cells without affecting
normal cells survival. Moreover, in THP-1 cells Morgana downregulation
enhances ROCK activity promoting cell proliferation while ROCK inhibition sig-
nificantly reduces the proliferation of these cells. Interestingly, we found that
the Morgana-ROCK pathway is altered in the 16% of Philadelphia-positive CML
patients where ROCK hyperactivation, cooperating with BCR-ABL signalling,
leads to imatinib resistance. In this context, treatment with a ROCK inhibitor
restores the efficacy of imatinib to induce apoptosis. In addition, we found Mor-
gana downregulation and ROCK hyperactivation in the bone marrow of all
aCML patients we tested. 
Summary/Conclusions: Taken together these results point out Morgana as
an oncosuppressor and ROCK as potential therapeutical target for Morganalow
CML patients. 
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Background: The introduction of specific BCR-ABL tyrosine kinase (TK)
inhibitors, especially imatinib mesylate (Gleevec), revolutionized the clinical
treatment of Chronic Myeloid Leukemia (CML). However, in many cases stable
remission cannot be sustained through several escaping mechanisms, such
as mutations in the ABL-kinase (e.g. T315I & M351T). These insights raise an
urgent need to develop alternative treatment strategies. An attractive approach
is targeting Heat Shock Protein 90 (Hsp90), which acts as a molecular chap-
erone and facilitates the folding of several oncogenic proteins including, BCR-
ABL.FDA approved Hsp90 inhibitors are available and show anti tumor activity
but to the best of our knowledge they all target the N terminal domain of Hsp90
and initiate heat shock response (HSR) with severe side effects (Wang &
McAlpine, 2015). Thus C-terminal Hsp90 inhibition can be an attractive
approach in targeting Imatinib resistant CML with low toxicity. We have identified
hotspots in the C-terminal domain of Hsp90 (Ciglia et al., 2014) and designed
several non-peptidic inhibitors, which target Hsp90’s C-terminal dimerization.
Aims: Generation and characterization of novel compounds targeting C termi-
nal dimerization of Hsp90 in vitro and in vivo.
Methods: The specificity of selected inhibitor (DDK88) to Hsp90 was deter-
mined by Hsp90 dependent luciferase refolding assay followed by efficacy
experiments using imatinib sensitive and resistant myeloid leukemic cell lines
in vitro as well as in in vivo Xenograft model.
Results: In the present study, we have extensively characterized a novel and
promising therapeutic compound (DDK88) for patients with Imatinib resistant
CML in vitro and in vivo. DDK88 exhibits anti-proliferative and cytotoxic activity
in several human myeloid leukemic cell line models (e.g. K562 - 5.72±0.31µM,
KCL-22 - 2.74±0.52µM) and induces cell cycle arrest, early differentiation and
inhibits colony formation. DDK88 disrupts Hsp90’s chaperone activity to BCR-
ABL protein. Hence in vitro application of DDK88 revealed down regulation of
BCR-ABL protein expression and its downstream signaling network including,
STAT5a, CRKL, AKT and mTOR proteins. Moreover, imatinib resistant CML
cell lines are equally sensitive to DDK88 (e.g. K-562r - 6.24±0.52 µM, KCL-22r
- 2.86±0.63µM) as compared to imatinib sensitive cells. In the same way,
DDK88 inhibits proliferation and BCR-ABL kinase activity of 3 clinically relevant
imatinib-resistant (~10 µM) BCR-ABL mutant (T315I, M351T & E255K - ~3µM)
cell lines. Notably, unlike clinical inhibitors targeting N-terminal (e.g. AUY922),
DDK88 does not induce HSR, evaluated by protein expression of HSF-1,
Hsp70, Hsp40 and Hsp27. DDK88 has a therapeutic window as its inhibitory
effects on healthy cord blood (CB) derived mononuclear cells (MNCs) and
CD34+ cells were significantly less potent as compared to the human leukemic
cell lines. Furthermore, in-vivo proof of concept studies demonstrate the efficacy
of DDK88 at 0.5 mg/kg in a K-562-Luciferase Xenograft tumor model. DDK88
reduced tumor burden with respect to tumor weight (DDK88 0.2±0.01g vs vehi-
cle 1.26±0.44g (p=0.04)). Immunoblot analysis of tumor samples derived from
DDK88 treated mice revealed the absence of HSR as well as downregulation
of BCR-ABL kinase activity and its associated downstream signaling pathways.
Summary/Conclusions: This study provides in vitro and in vivo characteriza-
tion of a novel anti-Hsp90 compound, which is specific against its C-terminus.
Hence further improvement and testing of DDK88 in pre-clinical studies can be
a promising strategy to target imatinib resistant CML and to avoid HSR.
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Background: Treatment of chronic myelogenous leukemia (CML) with BCR-
ABL tyrosine kinase inhibitors (TKI) achieves high rates of molecular response.
However, BCR-ABL-positive leukemic stem and progenitor cells persist implying
the need for lifelong treatment. Bone marrow stroma plays an important role in
inhibiting apoptosis. Cytokines such as interleukin 3 (IL-3) and
granulocyte/macrophage-colony stimulating factor (GM-CSF) mediate BCR-
ABL-independent survival of progenitor cells via common receptor subunit
CSF2RB. Disruption of the CSF2RB axis by the Janus kinase1/2-inhibitor rux-
olitinib overcomes cytokine-mediated resistance in vitro. We previously demon-
strated upregulation of CSF2RB in BCR-ABL-transformed cells as potential
resistance mechanism, and now provide an indepth molecular and functional
analysis.
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